Author

Rahma Ayadi

ANTI-MITOCHONDRIAL ANTIBODY-NEGATIVE PRIMARY BILIARY CHOLANGITIS: EPIDEMIOLOGICAL, CLINICAL, BIOLOGICAL, HISTOLOGICAL AND EVOLUTIONARY CHARACTERISTICS
ANTI-MITOCHONDRIAL ANTIBODY-NEGATIVE PRIMARY BILIARY CHOLANGITIS: EPIDEMIOLOGICAL, CLINICAL, BIOLOGICAL, HISTOLOGICAL AND EVOLUTIONARY CHARACTERISTICS

Rahma Ayadi  et al.

ANTI-MITOCHONDRIAL ANTIBODY-NEGATIVE PRIMARY BILIARY CHOLANGITIS: EPIDEMIOLOGICAL, CLINICAL, BIOLOGICAL, HISTOLOGICAL AND EVOLUTIONARY CHARACTERISTICS
ANTI-MITOCHONDRIAL ANTIBODY-NEGATIVE PRIMARY BILIARY CHOLANGITIS: EPIDEMIOLOGICAL, CLINICAL, BIOLOGICAL, HISTOLOGICAL AND EVOLUTIONARY CHARACTERISTICS

CELIAC DISEASE AND PERITONEAL TUBERCULOSIS: INCIDENTAL OR DOCUMENTED ASSOCIATION?
CELIAC DISEASE AND PERITONEAL TUBERCULOSIS: INCIDENTAL OR DOCUMENTED ASSOCIATION?

Rahma Ayadi  et al.

CAN SERUM FERRITIN PREDICT 30 DAYS MORTALITY IN PATIENTS WITH DECOMPENSATED CIRRHOSIS?
CAN SERUM FERRITIN PREDICT 30 DAYS MORTALITY IN PATIENTS WITH DECOMPENSATED CIRRHOSIS?

Rahma Ayadi  et al.

EXTERNAL VALIDATION OF NEW FIB-4 THRESHOLDS FOR RULING IN CHRONIC HEPATITIS B RELATED FIBROSIS
EXTERNAL VALIDATION OF NEW FIB-4 THRESHOLDS FOR RULING IN CHRONIC HEPATITIS B RELATED FIBROSIS

Rahma Ayadi  et al.

Item 1 - 5 / 5
1